Latest Breaking News On - Pacific merger sub inc - Page 1 : comparemela.com

Gilead Sciences Announces Expiration of Hart-Scott-Rodino Waiting Period for CymaBay Tender Offer

Gilead Sciences Announces Expiration of Hart-Scott-Rodino Waiting Period for CymaBay Tender Offer
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesGilead sciences incExchange commissionInnisfree ma incorporatedUs department of justiceCymabay therapeutics incGilead sciencesPacific merger sub incHart scott rodino antitrust improvements actCymabay therapeuticsPremerger notificationReport formsFederal trade commissionAntitrust divisionEastern time

CymaBay Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Corporate Update

CymaBay Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Corporate Update
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesSujal shahArran attridgeTheresa dolgeCymabay therapeutics incEuropean medicines agencyRegulatory agencyGilead sciences incExchange commissionClinical developmentKaken pharmaceutical co ltdLifesci advisorsDrug administrationPacific merger sub incBay reports fourth quarterYear ended december

CymaBay Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Corporate Update

CymaBay Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Corporate Update
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesSujal shahTheresa dolgeevoke kyneDrug administrationGilead sciences incPacific merger sub incClinical developmentExchange commissionRegulatory agencyPj kelleherlifesci advisorsCymabay therapeutics incKaken pharmaceutical co ltdEuropean medicines agencyGilead sciencesBay therapeuticsNew england journal

Gilead Sciences Expands Liver Portfolio With Acquisition of CymaBay Therapeutics

Gilead Sciences, Inc. (Nasdaq: GILD) and CymaBay Therapeutics, Inc. (Nasdaq: CBAY) announced today a definitive agreement under which Gilead will acquire CymaBay for $32.50 per share in cash or a total equity value of $4.3 billion. The addition of CymaBay’s investigational lead product candidate, seladelpar for the .

United statesSujal shahBofa securities incGilead sciencesCymabay therapeutics incX twitter gilead sciencesExchange commissionGuggenheim securitiesPacific merger sub incCenterview partnersDrug administrationGilead sciences incAdds seladelparPrimary biliary cholangitisThird quarterBest in disease profile